Philippe Barthélémy, Ph.D.
Affiliations: | 2000-2001 | Chemistry | Duke University, Durham, NC |
| 2005- | Université de Bordeaux, Talence, Nouvelle-Aquitaine, France |
Area:
amphiphile, DNA, drug deliveryWebsite:
http://chembiopharm.fr/Google:
"Philippe Barthélémy"Bio:
Barthélémy received his doctorate in chemistry from the University of Montpellier II, France in 1993. He was then a postdoctoral fellow at Emory University in the group of Pr Fredric Menger (Lavoisier Grant and Emory Fellowship). In 1995 he was appointed as a temporary lecturer at the University of Avignon and as Associate Professor at the same University in 1996. P. Barthélémy worked also as a Visiting Associate Professor at Duke University in 2001. In 2005 he was appointed as full Professor at the University of Bordeaux Segalen. He is leading the “ChemBioPharm” team of the INSERM U1212. Philippe Barthélémy was Vice President of the University of Bordeaux Segalen (2011-2013). Over the course of his tenure, Barthelemy’s research has yielded more than 110 peer-reviewed publications, more than 20 patents and patent applications, and more than 110 oral invited conferences and oral presentations.
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Tannir NM, Signoretti S, Choueiri TK, et al. (2020) Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-Line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Dessane B, Smirani R, Bouguéon G, et al. (2020) Nucleotide lipid-based hydrogel as a new biomaterial ink for biofabrication. Scientific Reports. 10: 2850 |
| Debien V, Thouvenin J, Lindner V, et al. (2019) Sarcomatoid Dedifferentiation in Renal Cell Carcinoma: From Novel Molecular Insights to New Clinical Opportunities. Cancers. 12 |
| Benizri S, Gissot A, Martin A, et al. (2019) Bioconjugated oligonucleotides: recent developments and therapeutic applications. Bioconjugate Chemistry |
| Guillot A, Joly C, Barthélémy P, et al. (2018) Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study. Clinical Genitourinary Cancer |
| Benizri S, Ferey L, Alies B, et al. (2018) Nucleoside-Lipid-Based Nanocarriers for Sorafenib Delivery. Nanoscale Research Letters. 13: 17 |
| Ramin MA, Sindhu KR, Appavoo A, et al. (2017) Cation Tuning of Supramolecular Gel Properties: A New Paradigm for Sustained Drug Delivery. Advanced Materials (Deerfield Beach, Fla.) |
| Kaplan JA, Barthélémy P, Grinstaff MW. (2016) Self-assembled nanofiber hydrogels for mechanoresponsive therapeutic anti-TNFα antibody delivery. Chemical Communications (Cambridge, England) |
| Oumzil K, Benizri S, Tonelli G, et al. (2015) pH-Cleavable Nucleoside Lipids: A New Paradigm for Controlling the Stability of Lipid-Based Delivery Systems. Chemmedchem. 10: 1797-801 |
| Camplo M, Raimundo JM, Navailles L, et al. (2014) Bioinspired systems in supramolecular chemistry and nanotechnology-introducing the SupraBio themed issue New Journal of Chemistry. 38: 5120-5121 |